De Cell

DeCell Technologies is a biotechnology company specializing in tissue engineering and regenerative medicine through its proprietary decellularization platform. The company develops biocompatible scaffolds by removing cellular material from donor tissues while preserving the structural and biochemical integrity of the extracellular matrix. Their product portfolio includes decellularized dermis, bone, and corneal tissues designed to facilitate natural tissue repair and regeneration. DeCell's technology addresses critical needs in wound care, ophthalmology, and orthopedic surgery by providing low-immunogenicity alternatives to traditional grafts. The company maintains a global presence with operations in South Korea and Canada, leveraging academic collaborations to advance its pipeline of regenerative therapies.